Please visit answersincme.com/860/IME_2025_00013162-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Toby Maher, MB, MSc, PhD, FRCP; and Justin Oldham, MD, MS. In this activity, experts explore advances in ILD care, including personalized, multidisciplinary approaches to integrate novel antifibrotic therapy and enhance patient engagement. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel antifibrotic therapy in interstitial lung disease (ILD); Apply the latest clinical data on novel antifibrotic therapy to therapeutic decision-making in ILD; and Outline multidisciplinary strategies to enhance the care of patients with ILD who are receiving antifibrotic therapies.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related